Related Experiment Videos
Current therapy of chronic liver disease
1University of Texas Medical Branch, Galveston.
Drugs
|June 1, 1990
Summary
Exploring treatments for chronic liver diseases like hepatitis and Wilson's disease, this review examines alternatives to d-penicillamine and discusses emerging therapies for autoimmune hepatitis and viral hepatitis B.
Area of Science:
- Hepatology
- Gastroenterology
- Internal Medicine
Background:
- Chronic liver diseases lack comprehensive pathogenetic understanding, hindering effective treatment strategies.
- Wilson's disease involves copper accumulation; current treatments have limitations.
- Various forms of hepatitis, primary sclerosing cholangitis, primary biliary cirrhosis, and alcoholic liver disease present unique therapeutic challenges.
Purpose of the Study:
- To review current and potential therapeutic strategies for diverse chronic liver diseases.
- To identify alternative treatments for conditions with limited or poorly tolerated standard therapies.
- To highlight areas requiring further research in liver disease management.
Main Methods:
- Literature review of existing studies on chronic liver disease treatments.
- Analysis of therapeutic options for Wilson's disease, autoimmune hepatitis, viral hepatitis B, primary sclerosing cholangitis, primary biliary cirrhosis, and alcoholic liver disease.
- Evaluation of the efficacy and tolerability of various pharmacological agents.
Main Results:
- Trientine, oral zinc, and unithiol show promise as alternatives for Wilson's disease.
- Prednisone and azathioprine are effective for autoimmune chronic active hepatitis; cyclosporine is under investigation.
- Interferon-alpha (IFN alpha), alone or with corticosteroids, shows efficacy in chronic active hepatitis B.
- Corticosteroids and methotrexate may play a role in primary sclerosing cholangitis (PSC).
- Treatments for primary biliary cirrhosis (PBC) have been largely disappointing.
- Androgens and propylthiouracil are being investigated for alcoholic liver disease.
- Colchicine may slow fibrosis in cirrhosis, but requires further proof.
Conclusions:
- Several alternative and emerging therapies show potential for managing chronic liver diseases.
- Further research is crucial to establish definitive treatment protocols for many liver conditions.
- Optimizing treatment requires addressing specific disease mechanisms and patient tolerability.